Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of multiple dose levels of Ad26.COV2.S as a two-dose schedule in healthy adults
2020-005801-14Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary endpoints (main study). Started Dec 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005801-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005801-14.